Ocular Therapeutix (OCUL) Institutional Ownership

59.21% of Ocular Therapeutix's stock is owned by institutional investors. Learn more on OCUL's institutional investor holdings.

Of the 217 institutional investors that purchased Ocular Therapeutix's stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Avoro Capital Advisors LLC ($4.82M), Millennium Management LLC ($4.18M), Assenagon Asset Management S.A. ($3.74M), Point72 Asset Management L.P. ($3.60M), Vanguard Group Inc. ($3.28M), Alliancebernstein L.P. ($3.26M), and Commodore Capital LP ($2.58M).

Institutional investors have bought a total of 49,143,637 shares in the last 24 months. This purchase volume represents approximately $551.37M in transactions.

Of the 54 institutional investors that sold Ocular Therapeutix's stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Janus Henderson Group PLC ($4.16M), Summer Road LLC ($2.78M), Deep Track Capital LP ($2.36M), Balyasny Asset Management L.P. ($1.43M), Adage Capital Partners GP L.L.C. ($1.31M), Assenagon Asset Management S.A. ($871.41K), and Rosalind Advisors Inc. ($818.70K).

Institutional investors have sold a total of 20,300,797 shares in the last 24 months. This volume of shares sold represents approximately $215.81M in transactions.